180 related articles for article (PubMed ID: 29178985)
21. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
[TBL] [Abstract][Full Text] [Related]
22. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
23. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
Conley PB; Delaney SM
Curr Opin Hematol; 2003 Sep; 10(5):333-8. PubMed ID: 12913786
[TBL] [Abstract][Full Text] [Related]
24. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
[TBL] [Abstract][Full Text] [Related]
25. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
26. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.
van Gestel MA; Heemskerk JW; Slaaf DW; Heijnen VV; Reneman RS; oude Egbrink MG
Arterioscler Thromb Vasc Biol; 2003 Mar; 23(3):518-23. PubMed ID: 12615691
[TBL] [Abstract][Full Text] [Related]
27. Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model.
Crescence L; Darbousset R; Caroff E; Hubler F; Riederer MA; Panicot-Dubois L; Dubois C
Thromb Res; 2021 Apr; 200():133-140. PubMed ID: 33610885
[TBL] [Abstract][Full Text] [Related]
28. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
29. Homozygous loss of mouse tetraspanin CD82 enhances integrin αIIbβ3 expression and clot retraction in platelets.
Uchtmann K; Park ER; Bergsma A; Segula J; Edick MJ; Miranti CK
Exp Cell Res; 2015 Dec; 339(2):261-9. PubMed ID: 26562164
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
31. P2Y12 receptor: platelet thrombus formation and medical interventions.
Moheimani F; Jackson DE
Int J Hematol; 2012 Nov; 96(5):572-87. PubMed ID: 23054651
[TBL] [Abstract][Full Text] [Related]
32. P2Y
Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
[TBL] [Abstract][Full Text] [Related]
33. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
34. Does the VerifyNow P2Y12 assay overestimate "therapeutic response" to clopidogrel? Insights using short thrombelastography.
Khanna V; Hobson A; Mikael R; Sambu N; Englyst N; Curzen N
Thromb Haemost; 2014 Jun; 111(6):1150-9. PubMed ID: 24671606
[TBL] [Abstract][Full Text] [Related]
35. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
36. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
37. Biology and pharmacology of the platelet P2Y12 receptor.
Storey RF
Curr Pharm Des; 2006; 12(10):1255-9. PubMed ID: 16611109
[TBL] [Abstract][Full Text] [Related]
38. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.
Mendolicchio GL; Zavalloni D; Bacci M; Corrada E; Marconi M; Lodigiani C; Presbitero P; Rota L; Ruggeri ZM
J Thromb Haemost; 2011 Feb; 9(2):373-82. PubMed ID: 21083646
[TBL] [Abstract][Full Text] [Related]
39. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
Tan GM; Lam YY; Yan BP
Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
[TBL] [Abstract][Full Text] [Related]
40. Differential proteomic analysis of platelets suggested target-related proteins in rabbit platelets treated with Rhizoma Corydalis.
Li CH; Chen C; Zhang Q; Tan CN; Hu YJ; Li P; Wan JB; Feng G; Xia ZN; Yang FQ
Pharm Biol; 2017 Dec; 55(1):76-87. PubMed ID: 27653279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
